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Abstract
Background
Appetite and symptoms, conditions generally reported by the patients with cancer, are
somewhat challenging for professionals to measure directly in clinical routine (latent condi-
tions). Therefore, specific instruments are required for this purpose. This study aimed to per-
form a cultural adaptation of the Cancer Appetite and Symptom Questionnaire (CASQ), into
Portuguese and evaluate its psychometric properties on a sample of Brazilian cancer
patients.
Methods
This is a validation study with Brazilian cancer patients. The face, content, and construct
(factorial and convergent) validities of the Cancer Appetite and Symptom Questionnaire,
the study tool, were estimated. Further, a confirmatory factor analysis (CFA) was con-
ducted. The ratio of chi-square and degrees of freedom (χ2/df), comparative fit index (CFI),
goodness of fit index (GFI) and root mean square error of approximation (RMSEA) were
used for fit model assessment. In addition, the reliability of the instrument was estimated
using the composite reliability (CR) and Cronbach’s alpha coefficient (α), and the invariance
of the model in independent samples was estimated by a multigroup analysis (Δχ2).
Results
Participants included 1,140 cancer patients with a mean age of 53.95 (SD = 13.25) years;
61.3% were women. After the CFA of the original CASQ structure, 2 items with inadequate
factor weights were removed. Four correlations between errors were included to provide
adequate fit to the sample (χ2/df = 8.532, CFI = .94, GFI = .95, and RMSEA = .08). The
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model exhibited a low convergent validity (AVE = .32). The reliability was adequate
(CR = .82 α = .82). The refined model showed strong invariance in two independent sam-
ples (Δχ2: λ: p = .855; i: p = .824; Res: p = .390). A weak stability was obtained between
patients undergoing chemotherapy and radiotherapy (Δχ2: λ: p = .155; i: p < .001; Res:
p < .001), and between patients undergoing chemotherapy combined with radiotherapy
and palliative care (Δχ2: λ: p = .058; i: p < .001; Res: p < .001).
Conclusion
The Portuguese version of the CASQ had good face and construct validity and reliability.
However, the CASQ still presented invariance in independent samples of Brazilian patients
with cancer. However, the tool has low convergent validity and weak invariance in samples
with different treatments.
Introduction
Cancer patients may report changes in appetite [1]. These changes may be described as a lack
of desire to eat, a change in the taste of food, and a perception of early satiety [1–3]. Changes in
appetite may manifest as changes in weight [4, 5]. Contributing factors include digestive dys-
functions such as nausea, vomiting, and constipation. Because of the complexity of underlying
factors contributing to changes in appetite, it can be important to assess appetite and related
symptoms of digestive disturbance to best guide clinical care.
Both the loss of appetite and the weight loss are common and troubling characteristics
related to cancer patients, especially to patients with cancer in advanced stages, patients refrac-
tory to treatment, or patients without treatment options [2]. Quinten et al. [6] evaluated appe-
tite and its relationship to survival in 1,314 patients with cancer, and found that patients with
better appetite lived longer.
After evaluating 3,047 cancer patients, Dewys et al. [7] found that symptoms such as nausea,
loss of appetite, and diarrhea can contribute significantly to weight loss. Additionally, the
authors found a significant reduction in the average survival time of patients with low weight,
as compared to those with normal weight, regardless of the tumor’s location. Subsequent stud-
ies have confirmed these findings [8–10].
It should be emphasized that appetite can be affected either by the disease, or by the treat-
ment, which can cause symptoms such as nausea, vomiting, constipation, and changes in taste
or pain [11–13].
Given the importance that appetite has on the response to several treatments [7] and on the
disease progression [8, 10], several psychometric instruments to measure it have been proposed
[14–17]. Among these, the Functional Assessment of Anorexia/Cachexia Therapy (FAACT)
questionnaire [14], the Appetite, Hunger and Sensory Perception (AHSP) questionnaire [15],
the Council on Nutrition Appetite Questionnaire (CNAQ) [16] and the Simplified Nutrition
Appetite Questionnaire (SNAQ) [16, 17] stand out.
Considering that appetite is a latent condition, i.e., not directly measurable, it is necessary to
evaluate the psychometric properties of data gathered with this instrument before using it, by
assessing its validity and reliability. Only then the data can be used with confidence ensuring
the validity of the results and conclusions reached with that data [18, 19].
CASQ and Brazilian Patients
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To assess appetite and symptoms specifically in cancer patients, Halliday et al. [20] pro-
posed the Cancer Appetite and Symptom Questionnaire (CASQ). The CASQ is a one-factor
instrument comprising 12 items that allow responses on a five-point Likert scale. The CASQ
was proposed in English, for the UK population, and so far does not have versions in any other
language. The CASQ was adapted from the Council on Nutrition Appetite Questionnaire
(CNAQ) [16] and four items were added to meet the characteristics of cancer patients [20].
Thus, this study aimed to develop a cultural adaptation of the CASQ, into Portuguese, and
to evaluate its psychometric properties on a sample of Brazilian cancer patients in curative and
palliative treatments.
Method
Study Design
The cross-cultural adaptation and validation of the Appetite and Symptom Questionnaire
involved three phases: Phase 1 (Transcultural adaptation), Phase 2 (Content validity), and
Phase 3 (Evaluation of the psychometric characteristics).
Phase 1: Transcultural Adaptation of the CASQ
Face Validity. To confirm face validity of the CASQ we used the methods proposed by
Guillemin et al. [21] and Beaton et al. [22]. The instrument was translated independently by
three bilingual translators who were native speakers of Portuguese, had English knowledge,
and had lived in an English speaking country. The translations were evaluated by the research-
ers of the present study, in order to obtain consensus on a single Portuguese version. This ver-
sion was back-translated by a bilingual translator whose mother tongue was English and
compared with the original CASQ.
The Portuguese version was then pre-tested on a group of 32 cancer patients to verify the
Misunderstanding Index (MI) of each item of the CASQ. Given that no item presented an
MI> 20%, it was not necessary to change any words and/or the grammatical construction of
the items. The Portuguese version was then evaluated by a team comprising three Portuguese
teachers and three experts in oncology to verify the semantic, idiomatic, cultural, and concep-
tual equivalence of the instrument to the original version.
Phase 2: Content Validity
The content validity of the CASQ was estimated utilizing the method proposed by Lawshe
[23]. During this stage, 12 judges who were experts in the field of Oncology and Nutrition
rated each item on the instrument according to its essentiality (“essential,” “useful, but not
essential,” and “not necessary”). The Content Validity Ratio (CVR) was computed, and the sig-
nificance was assessed according to the method proposed by Wilson et al. [16], adopting a sig-
nificance level of 5% (CVR12; .05 0.57). This stage complements and/or helps to decide
whether to remove/maintain instrument items. This decision can only be made after confirma-
tory factor analysis, that is, when items with low factor weight are present or where there is dif-
ficulty of adjusting the model to the sample (which is verified after assessment of all
psychometric properties), the items associated with this difficulty are identified and CVR is
used for decision making.
Phase 3: Evaluation of Psychometric Characteristics
Phase 3 was a cross-sectional study, with a non-probabilistic convenience sampling design.
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Participants. Patients attending the Barretos Cancer Hospital outpatient and inpatient
clinics with a diagnosis of malignant neoplasms were invited to take part. The sample selection
was performed for convenience (non-probabilistic). Those undergoing major and intermediate
complex surgical procedures within 30 days of the interview, with cognitive impairment or
severe psychiatric disorders, and under the age of 18 years were excluded from the sample. The
study included only cancer patients who agreed and signed the free and informed consent form.
Sample size calculation. The estimated minimum sample size was based on the require-
ment of 10 subjects per model parameter [24]. Given that the instrument (CASQ) had 24
parameters, the required sample size was 240. As the invariance of the instrument in two inde-
pendent samples was also evaluated in this study, it was necessary to use a second sample with
the same size. Therefore, the estimated minimum necessary sample size was 480 participants.
Given that this study also aimed to examine the psychometric qualities of the CASQ on cancer
patients in Brazil, it was considered that the sample was large enough to conveniently capture
the variability in this population [18]. Thus, we chose to work with a representative sample big-
ger than that recommended for the statistical analysis.
Study variables and instrument. To characterize the sample, demographics and clinical
information were collected. The socio-demographic data collected included gender, age, mari-
tal status, presence of any religious practices, work-related activity, number of people in the
household, and socioeconomic status and education of the head of the household. Age was
assessed in years; marital status in categories such as single, married, widowed, and separated/
divorced. The religion and its practice, and work-related activity were assessed dichotomously
(presence/absence). The economic and educational level of the head of the household were
classified according to the Brazil Criterion—ABEP [25].
Clinical information regarding the disease was obtained by consulting the patients’ clinical
record. The variables evaluated were the presence of a definite diagnosis (presence/absence),
type of neoplasm, stage, treatment type (chemotherapy, radiotherapy, chemotherapy and
radiotherapy, hormone therapy, and immunotherapy and palliative care) and metastasis (pres-
ence/absence). Information on the location of the patient at the time of assessment (outpatient
or inpatient) was also collected.
The height (cm) and weight (kg) reported by the patient were recorded for calculating the
body mass index (kg/m2) (BMI). To determine the classification of BMI, the cutoff points for
adults (> 20 years), proposed by the World Health Organization [26], were used.
Symptoms and appetite was assessed using the Cancer Appetite and Symptom Question-
naire (CASQ) developed by Halliday et al [20]. It should be clarified that four items of the
instrument had a reversed response scale. The author’s authorization was acquired before
using the instrument.
Data Analysis
Psychometric sensitivity. The summary and shape measures of the CASQ items’ distribu-
tion were used to estimate their psychometric sensitivity. Items with a skewness (Sk) greater
than 3 and kurtosis (Ku) greater than 7, in absolute values, were considered to have psychomet-
ric sensitivity issues [27]. The diagnosis of multivariate outliers was performed by computing
the Mahalanobis distance [27].
Construct validity. To assess the construct validity of the instruments the factorial and
convergent validity were evaluated.
Factorial validity. To examine the effectiveness of the adaptation of the CASQ to the
study sample, a Confirmatory Factor Analysis was performed using the Maximum Likelihood
estimation method implemented in SPSS AMOS (v.22, SPSS an IBM Company, Chigago, IL).
CASQ and Brazilian Patients
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To assess the goodness of the model fit to the data variance/covariance matrix, the ratio of chi-
square and degrees of freedom (χ2/df), comparative fit index (CFI), goodness of fit index (GFI)
and root mean square error of approximation (RMSEA) were used [19]. The fit of the model
was considered adequate when χ2/df 2.0, CFI and GFI .90 and RMSEA .08 for each
sample [19, 24].
Items that had factor weights (λ)< .30 were removed, as well as those that proved redundant
by the modification indices, estimated through the Lagrange multipliers (LM> 11, p< .001).
The modification indices were also used to verify the correlation between the items’ errors [19].
To define the best model (complete or refined) the indices based on information theory
were used, namely, the Akaike Information Criterion (AIC), Bayes Information Criterion
(BIC), and Browne-Cudeck Criterion (BCC), and the model that presented lower values in one
or more of these indices was considered the most parsimonious.
Factorial Invariance. To verify the invariance of the factor structure obtained, a cross-val-
idation of the model was performed by means of a multigroup analysis. For this, the sample
was randomly divided into two parts (6:4), 60% comprised the “Test Sample” and 40% the
“Validation Sample.” The invariance of the models was tested using the chi-square difference
(Δχ2) statistics between the two models. The model was considered invariant when Δχ2
p>0.05. The invariance of: i) factor weights (λ) (metric invariance/weak invariance), ii) factor
weights (λ) and items intercepts (i) (scalar invariance/strong invariance), iii) factor weights (λ),
items intercepts (i) and residuals variances/covariances (residuals invariance/strict invariance)
(Res) were tested [28].
The invariance of the factor model was also tested by subdividing the participants according
to treatment type (chemotherapy, radiotherapy, chemotherapy and radiotherapy, and palliative
care).
Convergent validity. The Average Variance Extracted (AVE) was used to assess the con-
vergent validity of the CASQ [19, 24]. Acceptable values (AVE .50) are indicative of the fac-
tor’s convergent validity) [24].
Reliability. The reliability of the CASQ was estimated by the Composite Reliability (CR)
and the standardized Cronbach’s coefficient alpha (α), which were considered adequate when
CR α .70 [29, 30].
Calculation of the appetite and symptom global score. After fitting the model to the
sample variance/covariance matrix data, the overall score for the “Appetite and Symptoms”
was calculated using a matrix of factor score weights produced by the fitted model [19]. This
weight was assigned to each item and was multiplied by the answer given by each participant,
after which all weighted items were summed, obtaining an overall score.
All analyses were performed using the IBM SPSS Statistics (v.22, SPSS An IMB Company,
Chicago, IL) and AMOS 22.0 (SPSS An IMB Company, Chicago, IL) programs.
Ethical Considerations
This study followed the ethical principles of Resolution 466/12 of the National Board of Health,
and was approved by the Research in Human Beings’ Ethics Committee of the Barretos Cancer
Hospital (Barretos-São Paulo) (protocol 561/2011).
Results
Face Validity
At the stage of face validity, the pre-test evaluation, there was a need to change only item 12
(presence and / or severity of pain), more specifically in its response scale. This change was
explained by the need to identify of Individuals without pain. Therefore, the response scale to
CASQ and Brazilian Patients
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that item was modified to 6 points: “no pain,” “very light,” “mild,” “moderate,” “severe,” and
“very severe” (thus, including the response no pain). No other adaptation was necessary.
Participants
A total of 1,219 patients with cancer, treated at the Cancer Hospital of Barretos (São Paulo -
Brazil) in 2013, were invited to participate. Of these 1,140 (93.5%) agreed to participate.
The reasons for not participating in to the survey were lack of time (n = 5), having already
participated in another study on the same day (n = 1), shyness (n = 2), not feeling well (n = 3),
refusal to fill out the demographic questionnaire (n = 1), no justification (n = 7), not wanting
to participate given that data collection was in an interview format (n = 60).
The mean age of the participants was 53.95 (SD = 13.25) years and only 1 patient was
reported to have no definite diagnosis. The sociodemographic and clinical characterization of
the participants has been presented in Table 1. It is important to note that not all patients
answered all the questions of the sociodemographic inventory (“religion” n = 16; “religion
practice” n = 15; “marital status” n = 2; “work activity” n = 3) and some clinical information
was not included in clinical records (“data collection location” n = 7; “stage" n = 33; “type of
treatment” n = 4; “presence of metastasis” (n = 6) and “Body Mass Index” n = 16).
Psychometric sensitivity and Content Validity
Table 2 presents the summary measures of the items of the Appetite and Symptoms Question-
naire for Cancer Patients Portuguese version, for patients with cancer, and the Content Validity
Ratio (CVR).
No items presented severe values of Sk and Ku, which indicates the adequate psychometric
sensitivity of the items. In the opinion of the judges/experts, 5 items (it2. When I eat I feel full,
it3. Before eating, I feel hungry, it4. I enjoy the food I do eat, it6. At present I eat in addition to
or instead of meals, it10. Most of the time my mood is) of the CASQ were not essential for the
assessment of appetite and symptoms.
Factorial and Convergent validity and Reliability
The confirmatory factor analysis (CFA) of the original CASQ structure and refined model fit-
ted to the Brazilian sample of patients with cancer is presented in Fig 1.
Two items presented inadequate factor weights (λ< .30). The fit of the original model to
the sample was unsatisfactory. For the CASQ to present an adequate fit to the sample, items
with λ< .30 were removed, and four correlations between errors were included (e1–e3, e4–e8,
e7–e8, e10–e11). The refined model presented adequate fit to sample and explained 64% of the
variance. Thus, the average variance extracted was below of the adequate (AVE = .32). The reli-
ability was adequate (CR and α = .82).
Table 3 presents the findings of the confirmatory factor analysis (CFA), average variance
extracted (AVE), composite reliability (CR) and internal consistency (α) of the refined CASQ
model fitted to different samples.
The refined model presented an adequate fit in all the tested samples, except for the sample
submitted to radiotherapy (RMSEA = .11). However, it is important to emphasize that a low
factor weight (λ = .10) was exhibited by the sample of palliative care patients for the item
regarding the presence/severity of pain (it 12).
The model presented low convergent validity, and the reliability (CR and α) was adequate.
CASQ and Brazilian Patients
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Appetite and symptom global score
After verifying the adequacy of the refined model to the sample, we determined the algorithm
for calculating the overall Appetite and Symptom score in the sample, as presented in Eq 1.
Apettite ¼ :171it1þ :125it2þ :026it3þ :138it4þ :153it7þ
þ:084it8þ :117it9þ :047it10þ :101it11þ :053it12 ð1Þ
For each item of the CASQ the scale of responses is scored from 0 to 4 and, in order to
obtain the overall CASQ score for each participant, the response given to each item should be
summed. In addition, strategies for evaluating the score obtained may be implemented. For
example, use of percentiles 25, 50 and 75 of the scale where a score 1 represents low
Table 1. Sociodemographic and Clinical Characterization of the study Participants.
Sociodemographic characteristics n % Clinical Characteristics n %
Gender Specialty of the Diagnosis*
Male 441 38.7 Head and Neck 79 6.9
Female 699 61.3 Upper digestive tract 108 9.5
Religion Lower digestive tract 222 19.5
No 49 4.4 Gynecology 135 11.8
Yes 1075 95.6 Hematology 5 0.4
Religious Practice Breast Cancer 335 29.4
No 156 13.9 Brain Tumor 17 1.5
Yes 969 86.1 Orthopedics 27 2.4
Marital status Skin 46 4
Single 155 13.6 Thorax# 66 5.8
Married 740 65.0 Urology 100 8.8
Widowed 128 11.2 Stage
Separated/Divorced 115 10.1 I 81 8.0
Work Activity II 233 23.1
No 843 74.1 III 371 36.8
Yes 294 25.9 IV 322 32.0
Economic Class Type of treatment
A 27 2.4 Chemotherapy 649 57.1
B 393 34.5 Radiotherapy 171 15.1
C 536 47.0 Chemotherapy and radiotherapy 150 13.2
D and E 184 16.2 Hormone-therapy 26 2.3
Data collection location Immunotherapies 20 1.8
Outpatient consultation 1051 92.8 Palliative care 120 10.6
Hospitalization Units 82 7.2 Presence of metastasis
No 627 55.3
Yes 507 44.7
Body Mass Index (BMI)
< 18.5 (Low weight) 78 6.9
18.5–25.0(Normal) 468 41.6
25.0–30.0 (Pre-obesity) 363 32.3
 30.0 (Obesity) 215 19.1
* The criterion adopted was based on the classiﬁcation presented by the Barretos Cancer Hospital following the subspecialties of Clinical Oncology
# Lung, pleura and mediastinum
doi:10.1371/journal.pone.0156288.t001
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impairment of the Appetite/ Symptoms, 1 to 3 moderate impairment and a score> 3 severe
impairment. We believe that the Appetite/Symptoms classiﬁcation could strategically be
adjusted by clinicians to reﬂect the level of their involvement in clinical practice.
Factorial Invariance
After verifying the best fit of the CASQ refined model to the sample, the invariance of the
model was evaluated in independent samples (Table 4).
The refined model showed strong invariance in the independent samples (Validation x
Test) and weak invariance in three subsamples (Chemotherapy × Radiotherapy,
Chemotherapy × Chemotherapy and Radiotherapy, Chemotherapy and
Radiotherapy × Palliative Care). The invariance of the factor structure was not similar among
the treatment types.
The Portuguese version of CASQ is given in S1 Appendix.
Discussion
The refined model showed strong invariance in independent samples (Validation × Test). The
invariance of the factor structure was not similar among the different treatment types.
For the structure of the CASQ to adequately fit the sample variance/covariance matrix, it
was necessary to remove Items 5 and 6 (Fig 1). One may speculate that, the low factor weights
found may be related with the difficulty in interpreting the term “meal.”
The term “meal” in Brazil often refers to a ritual of socialization that includes elements such
as the use of knife and fork, and sitting at the table [31]. In this sense, responses to this item
may have been influenced by this connotation, i.e., individuals may have had difficulty in
understanding that the concept of meal included any process of feeding and not only those sit-
uations involving the elements outlined above. However, it must be clear that this justification
was based on the reflection of the researchers on the low factor weights found and the theoreti-
cal construct regarding items 5 and 6. The respondents did not mention this difficulty in the
pilot study, which prevented changing the term “meal” during the creation of the Portuguese
Table 2. Summary Measures and Content Validity Ratio (CVR) for the Items of the Portuguese Version of the Appetite and SymptomsQuestion-
naire for Cancer Patients (CASQ).
CASQ Median Mean Mode Standard Deviation Skewness Kurtosis CVR*
It 1 1 1.55 1 1.15 0.44 -0.55 1.00
It 2 0 0.68 0 1.18 1.60 1.19 .33a
It 3 3 2.34 3 1.33 -0.38 -1.04 .00a
It 4 0 0.62 0 1.11 1.64 1.50 .33a
It 5 1 1.05 1 0.80 0.69 0.82 .83
It 6 3 2.71 3 1.02 -0.73 0.10 -.50a
It 7 2 2.45 2 0.73 0.27 0.66 .83
It 8 0 0.90 0 1.19 1.10 0.01 .67
It 9 0 0.73 0 1.14 1.48 1.24 .67
It 10 1 1.50 1 0.86 0.40 0.10 .00a
It 11 2 1.87 2 1.00 0.08 -0.27 .67
It 12 0 0.84 0 1.16 1.15 0.22 1.00
* CVR12; .05  .57
avalues below the minimum signiﬁcant CVR
doi:10.1371/journal.pone.0156288.t002
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version of the CASQ. This manifestation appeared in the final study where most respondents
(99.4%) understood the term meal as a ritual (table, fork, knife. . .), not considering the entire
process of consuming foods throughout the day (for example: snacks between meals). This fact
can also be confirmed by the answer pattern of items 5 and 6. Item 5 presents response bias to
lower frequency while item 6 presents the inverse pattern. This difficulty was not observed in
the English sample [20], in which the instrument was originally proposed, which is probably
due to the cultural differences of the respective samples.
Another aspect to be highlighted is the low factor weight of Item 12, referring to the painful
condition, especially in the sample of patients in palliative care (Table 3). This fact can be
attributed to the use of medication for effective control of cancer pain in these patients, which
may mask the presence and/or severity of the pain [32]. Thus, we suggest caution in the use/
interpretation of this item in samples of palliative care patients.
The proposed refined model presented adequate fit in the independent samples according
to treatment type (Table 3) and was invariant in the two independent samples and between
Fig 1. Factor structure of the original model CASQ. Factor structure of the original model (CFA: λ = .13–.81; χ2/df = 18.002, CFI = .761, GFI = .846
RMSEA = .122, AIC = 1,020.112, BCC = 1,020.666, BIC = 1,141.043, σ2 = 0,53) and the refined model fitted to the Brazilian sample of patients with cancer
(CFA: λ = .34–.70; χ2/df = 8.532, CFI = .936, GFI = .954, RMSEA = .081, AIC = 312.505, BCC = 312.973, BIC = 433.436, σ2 = 0,64).
doi:10.1371/journal.pone.0156288.g001
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patients who underwent Chemotherapy and Radiotherapy, Chemotherapy × Chemotherapy
and Radiotherapy, Chemotherapy and Radiotherapy × Palliative Care (Table 4). The absence
of invariance observed between the models fitted to palliative care patients (Table 4) may be
related to clinical differences, both regarding diagnosis and treatment. Patients in palliative
care take greater amounts of pain medication, having a greater organic weakness [32] and the
feeding process is, in most cases, compromised [33]. This, in turn, makes the assessment of
appetite different from that carried out in cancer patients undergoing other treatment modali-
ties. It should be noted however that the lack of invariance in some samples does not prevent
the use of the proposed evaluation of Appetite/Symptoms presented in this study for the
screening of this condition in patients with cancer. It should be noted that where there is a
need to compare specific groups (e.g. other clinical features and/or demographics) a new
model of fit should be calculated in order to check the feasibility of using the weights shown in
Eq 1, this being due to possible differences in operationalization of the construct. What we
have presented is a step by step validation process and algorithm which may be of use to other
oncology healthcare professionals.
Another important aspect is the low convergent validity (AVE) (Table 3) observed for the
CASQ in all samples, which can be attributed to the high variability found in the factor weights
of the items. This variability may suggest the existence of more than one factor for the CASQ,
Table 3. The Confirmatory Factor Analysis (CFA), Average Variance Extracted (AVE), Composite Reliability (CR) and Internal Consistency (α) of
the Refined Model CASQ Fitted to Different Samples.
CFA*
Sample n λ χ2/df CFI GFI rerrors RMSEA AVE CR α
Test 695 .33–.73 5.99 .93 .95 .25–.47 .09 .33 .83 .81
Validation 445 .34–.66 4.21 .93 .94 .27–.52 .08 .30 .81 .79
Chemotherapy 649 .31–.69 4.79 .94 .95 .26–.47 .08 .29 .79 .78
Radiotherapy 171 .37–.76 3.23 .90 .89 .34–.54 .11 .35 .83 .83
Chemotherapy and Radiotherapy 150 .31–.82 1.59 .97 .94 .10–.56 .06 .38 .85 .84
Palliative 120 .10–.80 1.58 .94 .92 .22–.34 .07 .30 .79 .78
*CFA: λ = factor weight, χ2/df = Ratio chi-square by the degrees of freedom, CFI = Comparative of Fit Index, GFI = Goodness of Fit Index, rerrors =
correlation between errors, RMSEA = Root Mean Square Error of Approximation; AVE = Average Variance Extracted; CR = Composite Reliability, α =
Standardized Cronbach’s alpha.
doi:10.1371/journal.pone.0156288.t003
Table 4. Multigroup Analysis of the CASQ’s refinedmodel on independent samples.
Δχ2#
Groups λ I Res
Test × Validation 4.75 (.855) 5.89 (.824) 15.88 (.390)
Chemotherapy × Radiotherapy 13.17 (.155) 88.66 (<.001) 53.63 (<.001)
Chemotherapy × Chemotherapy and Radiotherapy 8.12 (.522) 24.12 (.007) 58.54 (<.001)
Chemotherapy × Palliative Care 27.56 (.001) 145.22 (<.001) 243.37 (<.001)
Radiotherapy × Chemotherapy and Radiotherapy 21.44 (.011) 53.46 (<.001) 98.69 (<.001)
Radiotherapy × Palliative Care 40.16 (<.001) 158.71 (<.001) 194.69 (<.001)
Chemotherapy and Radiotherapy × Palliative Care 16.48 (.058) 90.87 (<.001) 63.78 (<.001)
# Δχ2:λ = factor weight, i = factor weight and items intercept; Res = residuals
doi:10.1371/journal.pone.0156288.t004
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perhaps delimiting Appetite and Symptoms. It should be noted that this study sought to test
the original proposal (unifactorial) and that future studies could be developed to evaluate new
theoretical proposals, such as, for example, a two-factor structure and/or a second-order hier-
archical model. However, it should be remembered that these proposals must be supported by
convincing theoretical foundations. We emphasize that the convergent validity limitation did
not affect the fit model. Therefore, it did not prevent the use of a single-factor proposal for the
assessment of Appetite and Symptoms in cancer patients.
Regarding the evaluation of Appetite and Symptoms, the original version of the CASQ pro-
poses a final score based on the sum of the responses to the items [20]. However, a score
derived from the sum of responses does not seem to be the best strategy, since the metric prop-
erties of an instrument are influenced by sample characteristics and, therefore, can change in
different samples [34, 35].
Thus, we suggest that the overall score is computed using the matrix of factor score weights
(Eq 1) [19, 35], which should be adjusted for each sample. Thus, the inclusion or exclusion of
items will not affect the calculation of the final score, and it will be more accurate, since the
weights of the items are computed for each sample. This preserves the important differences
between the items, which can be different for each population. This strategy will result in a
more accurate estimate of the score of appetite and symptoms.
Thus, this paper presents the results of a tool for assessment of appetite and symptoms in
cancer patients, with adequate psychometric properties, and with an individualized proposal
for calculating the final score. This may contribute to a more accurate diagnosis and, thus, a
more resolute clinical management strategy.
Conclusion
The Portuguese version of the CASQ presented good face and construct validity, and reliability.
However, the CASQ still presented invariance in two independent samples of Brazilian patients
with cancer. It has low convergent validity and weak invariance in samples with different
treatments.
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